当前位置: 首页 >> 检索结果
347. A call for health R&D prioritisation and governance mechanisms in Africa.
作者: Mosoka Papa Fallah.;Nebiyu Dereje.;Elvis Temfack.;Dathan M Byonanebye.;Jacqueline Weyer.;Polydor Ngoy Mutombo.;Wayengera Misaki.;Eastman Candace.;Alhaji Njai.;Nathalie Strub-Wourgaft.;Nelson Sewankambo.;Adu-Sarkodie Yaw.;Placide Mbala-Kingebeni.;Dougbeh-Chris Nyan.;Birkneh Tilahun Tadesse.;Christof Vinnemeier.;Luis Sambo.;Isaac Adewole.;Raji Tajudeen.;Jean Kaseya.
来源: Lancet. 2025年405卷10482期889-890页 353. Behavioural interventions to increase uptake of FIT colorectal screening in Scotland (TEMPO): a nationwide, eight-arm, factorial, randomised controlled trial.
作者: Kathryn A Robb.;Ben Young.;Marie K Murphy.;Patrycja Duklas.;Alex McConnachie.;Gareth J Hollands.;Colin McCowan.;Sara Macdonald.;Ronan E O'Carroll.;Rory C O'Connor.;Robert J C Steele.
来源: Lancet. 2025年405卷10484期1081-1092页
Uptake of colorectal cancer screening is suboptimal. The TEMPO trial evaluated the impact of two evidence-based, theory-informed, and co-designed behavioural interventions on uptake of faecal immunochemical test (FIT) colorectal screening.
356. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.
作者: Fatoumata Diallo.;Fadima C Haidara.;Milagritos D Tapia.;Clara P Dominguez Islas.;Mark R Alderson.;William P Hausdorff.;Lionel Martellet.;Nancy Hosken.;Dhananjay Kapse.;Prasad S Kulkarni.;Kelly Townsend-Payne.;Francesca Vanni.;Christine M Posavad.;Samba O Sow.;Karen L Kotloff.;Wilbur H Chen.; .
来源: Lancet. 2025年405卷10484期1069-1080页
Invasive meningococcal disease is a devastating public health problem for the African meningitis belt. We assessed the safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, Y, W, and X (NmCV-5) relative to a licensed, quadrivalent meningococcal conjugate vaccine (MenACWY-TT) when co-administered with routine childhood vaccines at ages 9 months and 15 months.
357. Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study.
作者: Vamshi Jogiraju.;Pallavi Pawar.;Jenna Yager.;John Ling.;Gong Shen.;Anna Chiu.;Emma Hughes.;Ramesh Palaparthy.;Christoph Carter.;Renu Singh.
来源: Lancet. 2025年405卷10485期1147-1154页
Long-acting antiretrovirals can address barriers to HIV pre-exposure prophylaxis (PrEP), such as stigma and adherence. In two phase 3 trials, twice-yearly subcutaneous lenacapavir was safe and highly efficacious for PrEP in diverse populations. Furthering long-acting PrEP efforts, this study assessed the pharmacokinetics and safety of two once-yearly intramuscular lenacapavir formulations.
360. Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials.
作者: Degu Jerene.;Kristian van Kalmthout.;Jens Levy.;Jason Alacapa.;Natasha Deyanova.;Tanyaradzwa Dube.;Andrew Mganga.;Bianca Tasca.;Alexsey Bogdanov.;Egwuma Efo.;Katya Gamazina.;Anna Marie Celina Garfin.;Volodymyr Kochanov.;Adrian Leung.;Norma Madden.;Noriah Maraba.;Christopher Finn McQuaid.;Liberate Mleoh.;Baraka Onjare.;Rachel Powers.;Yana Terleiva.;Job van Rest.;Agnes Gebhard.;Katherine Fielding.;Salome Charalambous.
来源: Lancet. 2025年405卷10485期1155-1166页
The impact of digital adherence technologies on tuberculosis treatment outcomes remains poorly understood. We investigated whether smart pillboxes and medication labels can reduce poor treatment outcomes in patients with tuberculosis.
|